A very recent systematic review and meta-analysis conducted by Potrelli et al. demonstrated that elderly patients (those aged 65 years) with advanced ER+ BC have good OS and PFS from CDK4/6 inhibitors [17]. This evidence concerns the gene CDK4 and breast cancer.